US Bancorp DE Sells 36,415 Shares of Edwards Lifesciences Co. (NYSE:EW)

US Bancorp DE reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 707,731 shares of the medical research company’s stock after selling 36,415 shares during the period. US Bancorp DE owned 0.12% of Edwards Lifesciences worth $46,703,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Park Avenue Securities LLC lifted its stake in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after acquiring an additional 108 shares during the period. City State Bank raised its stake in Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after buying an additional 130 shares during the last quarter. Choreo LLC lifted its holdings in Edwards Lifesciences by 4.1% in the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after buying an additional 153 shares during the period. Stableford Capital II LLC boosted its position in Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after acquiring an additional 159 shares during the last quarter. Finally, Purus Wealth Management LLC grew its holdings in Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after acquiring an additional 160 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $67.02 on Friday. The company has a market capitalization of $40.37 billion, a PE ratio of 9.67, a PEG ratio of 3.86 and a beta of 1.13. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The stock’s 50 day moving average price is $67.98 and its 200-day moving average price is $77.85. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The business’s revenue was up 8.9% on a year-over-year basis. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on EW. UBS Group cut their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Stifel Nicolaus lowered their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Royal Bank of Canada decreased their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, The Goldman Sachs Group cut their price objective on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Sixteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.